SUSCEPTIBILITY OF SPIROCHETES BORRELIA BURGDORFERI SENSU LATO TO ANTIBIOTICS IN VITRO

Publications

Share / Export Citation / Email / Print / Text size:

Postępy Mikrobiologii - Advancements of Microbiology

Polish Society of Microbiologists

Subject: Microbiology

GET ALERTS

ISSN: 0079-4252
eISSN: 2545-3149

DESCRIPTION

8
Reader(s)
35
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Related articles

VOLUME 56 , ISSUE 3 (April 2017) > List of articles

SUSCEPTIBILITY OF SPIROCHETES BORRELIA BURGDORFERI SENSU LATO TO ANTIBIOTICS IN VITRO

Tomasz Chmielewski * / Stanisława Tylewska-Wierzbanowska

Keywords : Borrelia burgdorferi, antibiotics

Citation Information : Postępy Mikrobiologii - Advancements of Microbiology. Volume 56, Issue 3, Pages 335-339, DOI: https://doi.org/10.21307/PM-2017.56.3.335

License : (CC BY-NC-ND 4.0)

Published Online: 22-May-2019

ARTICLE

ABSTRACT

Empiric therapy has been applied in the treatment of Lyme disease. This therapy is selected following the sensitivity analysis of the proposed drug in all species of bacteria which can cause a similar type of infection and on the basis of the clinical efficacy of antibiotic treatment. Established schemes based on data collected from many centers in the world, including type of antibiotic, dose and duration of his administration, and the stage and form of Lyme disease have been created. Number of in vitro methods of spirochetes susceptibility to antibiotics has been also developed. Unfortunately, the lack of standardization often makes it impossible to compare the results of MIC and MBC. Furthermore, little is known about the interactions of the various antimicrobial substances and spirochetes. There is a need for testing of clinical strains isolated from patients after treatment, which would explain the problems associated with “refractory” cases of Lyme disease. The paper presents the research on the antibiotic-spirochete interactions observed in vitro.

Content not available PDF Share

FIGURES & TABLES

REFERENCES

1. Aguero-Rosenfeld M.E., Wang G., Swartz I., Wormer G.P.: Diagnosis of Lyme borreliosis. Clin. Microbiol. Rev. 18, 484–509 (2005)

2. Ates L., Hansen-Hübner C., Norris D.E. Richter D., Kraiczy P., Hunfeld K.-P.: Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi. Ticks Tick Borne Dis. 1, 30–34 (2010)

3. Brouqui P., Badiaga S., Raoult D.: Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob. Agents Chemother. 40, 1552–1554 (1996)

4. Chmielewski T., Tylewska-Wierzbanowska S.: Interaction between Borrelia burgdorferi and mouse fibroblasts. Pol. J. Microbiol. 59, 157–160 (2010)

5. Comstock L.E., Thomas D.D.: Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect. Immun. 57, 1626–1628 (1989)

6. Feng J., Wang T., Shi W., Zhang S., Sullivan D., Auwaerter P. G., Zhang Y.: Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg. Microbes Infect. 3, e49 (2014)

7. Feng J., Auwaerter P.G., Zhang Y.: Drug combination against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS ONE, 10, e0117207 (2015)

8. Feng J., Zhang S., Shi W., Zhang Y.: Ceftriaxone pulse dosing fails to eradicate bio-like microcolony B. burgdorferi persisters which are sterilized by daptomycin/doxycycline/cefuroxime without pulse dosing. Front. Microbiol. 7, 1744 (2016)

9. Hunfeld K.-P., Kraiczy P., Wichelhause T.A., Schäfer V., Brade V.: Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglicosides against Borrelia burgdorferi isolates. Intern. J. Med. Microbiol. 15, 11–17 (2000)

10. Hunfeld K.-P., Brade V.: Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don’t known, and what we need to know. Wien. Klin. Wochenschr. 22, 659–668 (2006)

11. Hunfeld K.-P., Ruzic-Subljic E., Norris D. E., Kraiczy P., Strle F.: In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49, 1294–1301 (2005)

12. Hunfeld K.-P., Ruzic-Subljic E., Norris D. E., Kraiczy P., Strle F.: Risk of culture-confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance. Intern. J. Med. Microbiol. 296 Suppl. 40, 233–241 (2006)

13. Kraiczy P., Weigand J., Wichelhaus T. A., Heising P., Backes H., Schafer V., Acker G., Brade V., Hunfeld K.-P.: In vitro activities of fluorochinolones against the spirochete Borrelia burgdorferi. Antimcrob. Agents Chemiother. 45, 2486–2494 (2001)

14. Morgenstern K., Bajler G., Norris D. E., Kraiczy P., Hanssen-Hübner C., Hunfeld K.-P.: In vitro susceptibility of Borrelia spielmanii to microbial agents commonly used for treatment of Lyme disease. Antimicrob. Agents Chemother. 53, 1281–1284 (2009)

15. Obonyo M., Munderloch U. G., Fingerle V., Wilske B., Kurtti T.J.: Borrelia burgdorferi in tick cell culture modulates expression of outer surface proteins A and C in response to temperature. J. Clin. Microbiol. 37, 2137–2141 (1999)

16. Tylewska-Wierzbanowska S., Chmielewski T.: The isolation of Borrelia burgdorferi spirochetes from clinical material in cel line cultures. Zbl. Bakt. 286, 363–370 (1997)

17. Veinovic G., Cerar T., Strle F., Lotric-Furlan S., Maraspin V., Cimperman J., Ruzic-Sabljic E.: In vitro susceptibility of European human Borrelia burgdorferi sensu stricto strains to antimicrobial agents. Int. J. Antimicrob. Agents, 41, 288–291 (2013)

EXTRA FILES

COMMENTS